Summary This study was performed with the aim of discovering the characteristics and survival of patients with metastatic renal carcinoma who undergo immunotherapy with an Interleukin 2 based regimen.
Most conventional systemic therapies have little or no activity in advanced renal carcinoma Yagoda et al., 1989) . Immunotherapy with Interferon or Interleukin-2 (IL2), used alone or in combination, has proved to be active in this disease, leading to response rates ranging from 15 to 30% (Quesada et al., 1983; Krown, 1987; Bergerat et al., 1988; Rosenberg et al., 1987; 1989a,b; West et al., 1987; Negrier et al., 1989; Atzpodien et al., 1990) . However, the toxicity induced by these cytokines is of great concern and raises the question of the justification of this treatment modality (Moertel, 1986) . According to previous studies, the median survival time is of 6 to 12 months in patients with metastatic renal carcinoma (Maldazys et al., 1986; Ritchie et al., 1987; Forges de et al., 1988; Philip et al., 1989) . Very few consistent data are available yet in the literature concerning the impact of immunotherapy on survival (Palmer et al., 1992a) . The present study was undertaken first to analyse the whole cohort of patients accrued during almost 4 years. We studied their characteristics, prognostic factors as well as their survival, considering whether they received cytokine therapy or not. Secondly, we analyse the differences of this cohort when compared to our historical group.
Patients and methods
Patients and treatments Three different groups of patients have been defined in this study; their main characteristics are detailed in Table I . All therapeutic protocols using unregistered drugs were conducted after local ethical committee acception and patient informed consent.
Almost all patients (at least those included in phase II trials i.e. 162/181) accrued after initiation of our immunotherapy programme, underwent the same investigation procedures to assess eligibility and to screen tumour localisations. Cranial, thoracic, abdominal and pelvic CT scan, bone scintigraphy and blood controls of major organ functions were performed.
Patients receiving cytotoxic regimens were reevaluated with at least thoracic and abdominal CT scans combined with other procedures if necessary.
Included patients
One hundred and twenty-nine patients were treated with cytokines within the immunotherapy programme. Sixty of these patients received IL2 as a continuous infusion (Eurocetus BV Amsterdam, The Netherlands) at 18 x 106 lU/M2/ day, according to the schedule previously reported by West et al. (1987) ; LAK cells were associated with IL2 infusion in 22 patients. Thirty-four patients received intravenous IL2 combined with Interferon alpha (IFN) (Schering Plough, Paris, France) according to the following schedule: one subcutaneous injection of IFN at 20 x 106/IU per day for 5 days then, after a 2-day rest, IL2 as bolus doses at 24 x 106 IU/ m2 q 3/day combined with intravenous IFN at 5 x 106 IU/ m2 q 3/day for 5 days. After a 6-day break, during which cytaphereses were performed in order to develop LAK cells, the same intravenous combined schedule was carried on for five additional days along with the LAK cell reinjection. Twenty-five patients received a combination of subcutaneous IL2 and IFN according to the schedule of Atzpodien et al. (1990) , previously described. Ten patients, who had received IFN therapy before being referred to our institute were treated with a combined therapy of IL2 and Tumor Necrosis Factor (TNF), as previously reported . Br. J. Cancer (1993 ), 68, 1036 -1042 '." Macmillan Press Ltd., 1993 
Statistical analysis
The parameters taken into account in the present study, when available, were those considered in previous reports on prognostic factors in metastatic renal carcinoma (Forges de et al., 1988; Elson et al., 1988; Palmer et al., 1992b According to the survival curves shown in Figure 1 , the median survival time of the control group, of the excluded group and of the treated group are respectively 8, 6 and 18 months. The difference between the excluded group and immunotherapy treated patients is significant (RR: 2.28; P< 10-6) whereas it is not different between the excluded and the control group (RR: 1.01; P = 0.94). As shown in Figure 2 , excluded patients were pooled together with treated patients and the median survival time was then of 15 months. The difference between this population and the control group remains significant (RR: 1.85; P = 10-5).
When the survival from the date of initial diagnosis is considered, the median times of follow-up are 43, 37 and 103 months respectively in the immunotherapy, the excluded and the control groups, with a respective median survival of 24, 9 and 13 months (Figure 3 ). The survival difference between the excluded group and the immunotherapy treated patients is significant (RR: 1.88; P = 10-4). Figure 4 shows the survival from initial diagnosis of both groups brought together. The median survival is then of 20 months and remains significantly different from that of the control group (RR: 1.37; P = 0.02).
Discussion
Even if rigorous criteria, such as WHO criteria for tumour evaluation are used, the efficacy of immunotherapy with Interleukin 2 in solid tumours has been judged until now mainly on the response rates of non randomised phase II studies (Rosenberg et only a minority of patients whereas its related toxicity concerns all of them (Siegel et al., 1991) . We thus attempted to analyse the survival and the characterstics of patients with metastatic renal carcinoma who were referred to our institute, whether they received immunotherapy or not.
The most conspicuous conclusion that can be drawn from this study is that patients eligible to receive immunotherapy are selected. Indeed, 29% of our patients were excluded from IL2 protocols. This group, as shown by the analysis of their characteristics and prognostic factors as well as their sur- Months from initial diagnosis treated patients together with excluded patients vs control group from initial diagnosis. -------Control group n = 64. The survival rate at 5 years (60 months) was: -IL2 + excluded: 26% -Control: 15% (confidence interval± 1O%).
vival, represents a bad prognosis group with a limited survival (e.g. median survival of 6 months after occurrence of metastases). These selection biases lead to an artefactual improvement of the survival of treated patients when compared to the overall survival of the population suffering from the same disease.
Selection of patients is not restricted to this kind of therapy, but is a common problem in the evaluation of treatments, specially in oncology (Peto et al., 1976; 1977) .
Very few authors, however, mention the exclusion rate of their clinical trials, but they draw conclusions from a selected group that are often taken into account for the whole population. We thus think that the reports of phase II trials in oncology should indicate the concomittent exclusion rate.
If we consider patients as a whole, whether treated with immunotherapy or not, the median overall survival is 16 months after occurrence of metastases. Since the literature reports no series with a median survival time over 1 year, we attempted to appreciate the factors that could be responsible for this improvement. With this aim, we analysed our historical control group, i.e. patients referred to our institute during the 5 years preceding initiation of the immunotherapy programme, in which the median survival is of 8 months. Such a median survival of 8 months has also been reported in another cohort of French patients with the same disease receiving different regimens of chemotherapy as phase II trials (Forges de et al., 1988) . Our results were weakened by the lack of two important prognostic factors which were not available in the retrospective cohort; i.e., weight loss and performance status.
Performance status appeared in three previous studies as a very powerful prognostic factor ( de Forges, 1988; Elson 1988; Palmer, 1992b 1,
of patients who did not undergo nephrectomy within the control group. Control patients received fewer systemic therapeutic lines than the immunotherapy treated patients, and this parameter might influence their survival as well. Conversely, we note that the number of control patients with more than two tumour sites is reduced, as well as the number of patients with lung and liver metastases. This difference in the number of metastatic sites would indicate that, despite a larger tumour burden, the survival of patients treated recently has been significantly improved. We must, however, point out that this last parameter should be considered with caution since the detection of metastatic sites was very different in these two cohorts. In fact, in the control group, metastatic lesions were merely detected when they became symptomatic, whereas a complete initial screening was performed in almost all the patients belonging to the second cohort, i.e. at least all patients in phase II trials (162/181: 89%). For this reason, the bulk of the disease was probably underestimated in our historical group.
As a result of selection bias and lead time bias, the two populations are obviously different. For this reason, it is not possible to appreciate the role of immunotherapy in the improved survival observed in recent patients. Notably, the starting point of survival evaluation, i.e. initial diagnosis vs first metastases, does not influence the results of our study, but reduced the difference in survival. Indeed, the survival of the control group appeared somewhat more favourable when analysed from initial diagnosis, whereas the shape of the curve is not modified in the prospective group. We hypothetised that the diagnosis of metastases has been done later in the course of the disease in the control than in the prospective group.
This analysis emphasises the impact of a new specific therapeutic programme and the management or follow-up modifications induced by the close evaluation of controlled trials (Osband et al., 1990) .
As a consequence, survival evaluation, especially for immunotherapy in metastatic renal cancer, is difficult. The most logical and objective way to appreciate the real impact of immunotherapy on survival would be to compare, within a prospective randomised trial, a treated group vs a placebo group. This situation, however, is ethically unfair since we know that immunotherapy can bring, although in only some patients, durable complete remissions.
Therefore, we now have to appreciate the response rate and survival of patients treated with different cytokine schedules in prospective multicentric trials and to try and evidence the predictive factors of response to therapy. Such a study is presently ongoing in France in metastatic renal carcinoma.
In summary, this study shows that the administration of immunotherapy with cytokines results in a selection of patients with the exclusion of a poor survival group. Therefore, the exclusion rate should also be investigated and reported in phase II trials in this setting. It also demonstrates the impact of a new therapeutic modality on referrals of a disease. The survival of patients with metastatic renal carcinoma treated with immunotherapy remains to be investigated specifically in a prospective and comparative setting.
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